MARKET

GLYC

GLYC

GlycoMimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.230
+0.010
+0.31%
After Hours: 3.230 0 0.00% 16:42 10/23 EDT
OPEN
3.220
PREV CLOSE
3.220
HIGH
3.330
LOW
3.160
VOLUME
439.49K
TURNOVER
--
52 WEEK HIGH
6.72
52 WEEK LOW
1.820
MARKET CAP
154.15M
P/E (TTM)
-2.8261
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
GlycoMimetics' Possible Rivipansel Revival
GlycoMimetics is undervalued based on its AML therapy potential.Rivipansel may have value despite the Phase 3 trial failure.Cash is sufficient to get to results.
Seekingalpha · 10/13 22:11
Have Insiders Been Buying GlycoMimetics, Inc. (NASDAQ:GLYC) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 10/12 12:28
GlycoMimetics Announces That It Entered Into A Sales Agreement With Cowen & Co. GlycoMinmetics May Offer And Sell Shares Having Offering Price Of Up To $100M
-Reuters
Reuters · 10/07 20:25
GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status
GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.
Zacks · 10/06 15:31
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
Benzinga · 10/06 12:24
AYX, LTHM among premarket gainers
Westwater Resources (WWR) +53%.Xtant Medical Holdings (XTNT) +29% after regaining compliance with NYSE's continued listing standards.Alteryx (AYX) +25% on raising Q3 revenue guidance.CBAK Energy Technology (CBAT) +22%.Ocean Power Technologies (OPTT) +20%.Oxbridge Re Holdings (OXBR)
Seekingalpha · 10/06 12:23
AYX, EEX, IOVA and YMAB among after-hours movers
Gainers: [[AYX]] +27.9%. [[EEX]] +24.1%. [[GLYC]] +15.0%. [[OR]] +8.3%. [[SPAQ]] +4.3%.Losers: [[IOVA]] -22.0%. [[YMAB]] -20.6%. [[KC]] -7.5%. [[DESP]] -4.6%. [[PDI]] -3.9%.
Seekingalpha · 10/05 21:32
GlycoMimetics's rivipansel nabs US Rare Pediatric status for sickle cell
GlycoMimetics (GLYC) jumps 17% after hours on FDA Rare Pediatric Disease tag for Rivipansel for the treatment of sickle cell disease.Rivipansel, a glycomimetic drug candidate that binds to all three members of
Seekingalpha · 10/05 20:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLYC. Analyze the recent business situations of GlycoMimetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLYC stock price target is 9.25 with a high estimate of 15.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 140
Institutional Holdings: 55.13M
% Owned: 115.52%
Shares Outstanding: 47.72M
TypeInstitutionsShares
Increased
33
2.38M
New
36
1.61M
Decreased
21
3.73M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Independent Director
Timothy Pearson
President/Chief Executive Officer/Co-Founder/Director
Rachel King
Co-Founder/Senior Vice President/Chief Scientific Officer
John Magnani
Chief Financial Officer
Brian Hahn
Senior Vice President
Armand Girard
Senior Vice President
Helen Thackray
Independent Director
Patricia Andrews
Independent Director
Mark Goldberg
Independent Director
Scott Jackson
Independent Director
Daniel Junius
Independent Director
Scott Koenig
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.